About this book:

The book traces Novo Nordisk’s origins to the 1921 discovery of insulin in Toronto and the parallel Danish efforts of Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium to bring this breakthrough to patients. Founded on scientific rigor, entrepreneurial ingenuity, and a shared humanitarian mission, the two companies navigated early production challenges, world wars, and postwar expansion, each advancing insulin purity, formulation (such as NPH insulin), and delivery devices like the Novo Syringe and NovoPen. Their rivalry spurred innovation, ultimately leading to the 1989 merger that created Novo Nordisk A/S, combining Nordisk’s research strength with Novo’s practical, patient‑centric approach.

Post‑merger, Novo Nordisk embraced recombinant DNA technology to produce human insulin and expanded beyond diabetes into growth hormone (Norditropin®) and hemophilia (NovoSeven®) therapies, leveraging its biotechnology expertise. The company built a global presence through subsidiaries, partnerships, and localized adaptation, while continually improving insulin analogues (Novolog®, Levemir®) and delivery systems (insulin pens, smart devices). Corporate culture emphasized the Triple Bottom Line—financial, social, and environmental performance—underpinned by strong R&D, manufacturing excellence, and a commitment to quality and accessibility.

In the 21st century, Novo Nordisk addressed rising metabolic epidemics with GLP‑1 receptor agonists (Victoza®, Ozempic®) and their higher‑dose obesity treatments (Saxenda®, Wegovy®), expanding into holistic chronic disease management. It integrated digital health tools, pursued oral and glucose‑responsive insulin, and explored cell‑based cures for type 1 diabetes. Throughout, the firm balanced scientific innovation with corporate social responsibility, sustainability, and equitable access, positioning itself as a global leader in diabetes, obesity, and broader biopharmaceutical care, driven by a century‑long legacy of patient‑focused innovation.

What You'll Find Inside:

• The revolutionary discovery of insulin that transformed diabetes from a fatal diagnosis to a manageable chronic condition, setting the foundation for Novo Nordisk's mission
• The parallel founding and eventual 1989 merger of Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium, combining academic rigor with entrepreneurial innovation
• Strategic diversification beyond insulin into growth hormone therapy (Norditropin®), hemophilia treatments (NovoSeven®), and obesity management (Saxenda®, Wegovy®)
• Pioneering advancements in biotechnology, insulin analogues, and delivery systems (from Novo Syringe to smart insulin pens) that revolutionized diabetes care
• Global expansion driven by Danish corporate values, commitment to corporate social responsibility, and a 'Triple Bottom Line' approach to financial, social, and environmental performance

Who's It For:

This book is ideal for business students, healthcare professionals, and anyone interested in the history of medical innovation and pharmaceutical development. It provides valuable insights for professionals in the diabetes care industry, researchers studying chronic disease management, and readers fascinated by how companies balance scientific innovation with social responsibility. The detailed account of Novo Nordisk's journey from insulin discovery to global leadership offers lessons in corporate strategy, adaptation to global challenges, and sustaining innovation over a century. Employees, investors, and stakeholders of Novo Nordisk would particularly benefit from understanding the company's heritage, values, and evolution.